The Directors of Chapmans Limited (ASX:CHP) are pleased to announce that the Company has successfully completed it's strategic investment in MJ Life Sciences Pty Ltd referred to in the Company's previous announcements of 23 and 29 August.
Zelda Therapeutics Ltd
Zelda Therapeutics (ASX:ZLD) (OTCMKTS:ZLDAF) is an Australian-based bio-pharmaceutical company focused on a series of clinical and pre-clinical programmes utilising cannabinoid-based medicines. Zelda has secured exclusive, global access to an extensive set of human data related to medicinal cannabis based formulations and treatment protocols. This human data has been generated over several years by a California-based group (Aunt Zelda’s) that has a very high profile within the USA and a growing international profile based upon its deep knowledge of the scientific rationale for certain cannabis-based formulations and protocols to treat a variety of medical conditions.
Zelda has embarked on a programme of human clinical trials initially in sleep disorder (insomnia), autism and eczema indications.
In addition, Zelda is building a pre-clinical research portfolio targeting cancer. It has partnered with the world’s leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer.
The Directors of Chapmans Limited (ASX:CHP) are pleased to announce that the Company has entered into a Binding Heads of Agreement with MJ Life Sciences Pty Ltd, to make a strategic investment of US$500,000 in MJLS.
The Directors of Chapmans Limited (ASX:CHP) (Chapmans, the Company) are pleased to provide the following update on it's investments and activities.
The Directors of Chapmans Limited (ASX:CHP) are pleased to announce that its specialist wholly owned medicinal cannabis subsidiary, Cannabis Investments Limited, has entered into a Term Sheet with AZ Pharmaceuticals Inc., the owner of the Aunt Zelda's medicinal cannabis business, to invest USD 2 million in Aunt Zelda's.
GLENEAGLE GOLD LIMITED ASX: GLN - Development on Track at the Fortnum Gold Project - Mr Ian Prentice, Managing Director
GLENEAGLE GOLD LIMITED (ASX: GLN) - Development on Track at the Fortnum Gold Project - Mr Ian Prentice, Managing Director; Boardroomradio is pleased to announce that GLENEAGLE GOLD LIMITED (ASX: GLN)